The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Ho Sup | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.contributor.author | Lee, Je-Jung | - |
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Yoon, Dok Hyun | - |
dc.contributor.author | Eom, Hyeon-Seok | - |
dc.contributor.author | Lee, Hyewon | - |
dc.contributor.author | Lee, Won Sik | - |
dc.contributor.author | Shin, Ho-Jin | - |
dc.contributor.author | Lee, Ji Hyun | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Jo, Jae-Cheol | - |
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Lee, Mark Hong | - |
dc.date.accessioned | 2021-09-04T00:00:31Z | - |
dc.date.available | 2021-09-04T00:00:31Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-05 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/88710 | - |
dc.description.abstract | In real clinical settings (not clinical trials), thalidomide has been accepted as maintenance therapy to patients with multiple myeloma (MM) because of the cost of drugs, the limitations of medical insurance, etc., in our country (South Korea). The purpose of this study was to evaluate the utility of thalidomide maintenance for improving survival in transplantation-eligible patients with MM in the real clinical field. Differences in survival rates were estimated in patients treated with or without thalidomide maintenance. The 3-year progression-free survival rates (PFS) of patients with and without maintenance, respectively, were 55.4 and 37.2 % (p = 0.005). The 3-year overall survival rates (OS) were 88.0 and 84.0 % (p = 0.105). No difference in 3-year OS after relapse or progression (OS2) was observed between the two groups (50.4 and 55.3 %, p = 0.661). The 3-year PFS of patients with and without maintenance therapy who had shown less than CR after ASCT were 68.4 and 23.3 % (p < 0.001). In conclusion, Thalidomide maintenance therapy showed longer PFS in real clinical practice, and long-term use of thalidomide did not interfere with the efficacy of salvage chemotherapy in patients who experienced progression or relapse after ASCT. In addition, thalidomide maintenance might be also useful for patients who have shown less than CR after ASCT. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | RANDOMIZED PHASE-3 | - |
dc.subject | RENAL-FAILURE | - |
dc.subject | THERAPY | - |
dc.subject | SURVIVAL | - |
dc.subject | DEXAMETHASONE | - |
dc.subject | LENALIDOMIDE | - |
dc.subject | METAANALYSIS | - |
dc.subject | COMBINATION | - |
dc.subject | CONSENSUS | - |
dc.subject | TRIALS | - |
dc.title | The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Yong | - |
dc.identifier.doi | 10.1007/s00277-016-2660-8 | - |
dc.identifier.scopusid | 2-s2.0-84962757622 | - |
dc.identifier.wosid | 000375556900007 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, v.95, no.6, pp.911 - 919 | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.citation.title | ANNALS OF HEMATOLOGY | - |
dc.citation.volume | 95 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 911 | - |
dc.citation.endPage | 919 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | RANDOMIZED PHASE-3 | - |
dc.subject.keywordPlus | RENAL-FAILURE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | DEXAMETHASONE | - |
dc.subject.keywordPlus | LENALIDOMIDE | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | CONSENSUS | - |
dc.subject.keywordPlus | TRIALS | - |
dc.subject.keywordAuthor | Multiple myeloma | - |
dc.subject.keywordAuthor | Thalidomide | - |
dc.subject.keywordAuthor | Transplantation | - |
dc.subject.keywordAuthor | Maintenance | - |
dc.subject.keywordAuthor | Survival | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.